The expression of CLCA2 has been verified to correlate with poor clinical outcomes in the breast cancer patients, while the impact of reduced CLCA2 expression on survival has not yet been studied in the patients with other types of cancer. This evidence concerns the gene CLCA2 and breast carcinoma.